Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1982-3-13
|
| pubmed:abstractText |
Pharmacokinetics of the investigational cephalosporin ceftriaxone were studied after 30-min intravenous infusions of three ascending single doses of 0.5, 1, and 2 g crossed over in 12 normal subjects. Serially collected plasma and urine samples were analyzed for ceftriaxone by high-performance liquid chromatography. Plasma concentration-time profiles were characterized by a linear two-compartment open model with the following respective mean (+/- standard deviation) parameters at 0.5-, 1-, and 2-g dose levels: elimination half-life, 6.5 +/- 0.7, 6.2 +/- 0.8, and 5.9 +/- 0.7 h; apparent volume of distribution, 8.5 +/- 1.1, 9.0 +/- 1.1, and 10.1 +/- 1.0 liters; and plasma clearance, 929 +/- 150, 1,007 +/- 130, and 1,190 +/- 150 ml/h. The respective renal excretion parameters were as follows: renal clearance, 373 +/- 60, 399 +/- 50, and 533 +/- 128 ml/h; and percentage of dose excreted unchanged in the 48-h urine samples, 41 +/- 8, 39 +/- 5, and 43 +/- 10. The 6-h elimination half-life of ceftriaxone was 2- to 10-fold longer than those reported for marketed and other known investigational cephalosporins. The small dose-related increases in the apparent volume of distribution and clearance parameters can be explainhe 48-h urine samples, 41 +/- 8, 39 +/- 5, and 43 +/- 10. The 6-h elimination half-life of ceftriaxone was 2- to 10-fold longer than those reported for marketed and other known investigational cephalosporins. The small dose-related increases in the apparent volume of distribution and clearance parameters can be explainhe 48-h urine samples, 41 +/- 8, 39 +/- 5, and 43 +/- 10. The 6-h elimination half-life of ceftriaxone was 2- to 10-fold longer than those reported for marketed and other known investigational cephalosporins. The small dose-related increases in the apparent volume of distribution and clearance parameters can be explained by the concentration-dependent plasma protein binding of ceftriaxone in humans. The impact of the small dose-dependent changes in the pharmacokinetics of ceftriaxone is anticipated to be of negligible clinical significance.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-101128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-119786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-314774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-316988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-485125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-525994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-538442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6245831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6248221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6252833,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6252837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6446398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6447137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6778381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6778383,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6967869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6969574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-6972194,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-7053242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-7249795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-7410283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275779-7447404
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0066-4804
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
634-41
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:6275779-Adult,
pubmed-meshheading:6275779-Cefotaxime,
pubmed-meshheading:6275779-Ceftriaxone,
pubmed-meshheading:6275779-Female,
pubmed-meshheading:6275779-Humans,
pubmed-meshheading:6275779-Injections, Intravenous,
pubmed-meshheading:6275779-Kinetics,
pubmed-meshheading:6275779-Male,
pubmed-meshheading:6275779-Middle Aged
|
| pubmed:year |
1981
|
| pubmed:articleTitle |
Pharmacokinetics of ceftriaxone in humans.
|
| pubmed:publicationType |
Journal Article
|